Clinical Trial Update: MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED) [Phase 3]

View source ↗

Summary

A Phase 3 trial of maraviroc (MK0518) in HIV-infected patients switched from a protease inhibitor regimen was terminated, with results posted on 2009-12-01.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Selzentry (Maraviroc) (Maraviroc)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infection | Phase 3 | Status: TERMINATED | Results posted: 2009-12-01